PARP inhibitors including olaparib, rucaparib, niraparib, and talazoparib have shown robust efficiency in breast cancer patients with germline BRCA1/2 mutation both as second-line therapy and as first-line therapy [23–25]. The gene discussed is BRCA1; the disease is breast cancer.